TP53 (Ab-15) Antibody

What are the recommended applications for TP53 (Ab-15) Antibody?

The TP53 (Ab-15) Antibody has been validated for multiple experimental techniques including Western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA) . For Western blot applications, the recommended dilution typically ranges from 1:500 to 1:1000, though optimal concentrations should be determined experimentally for each specific application . In immunohistochemistry, dilutions of 1:50 to 1:200 are commonly used to achieve optimal staining with minimal background . The antibody performs effectively in detecting p53 in both cell lysates and tissue sections, providing researchers flexibility in experimental design . Additionally, the antibody can be used in immunoprecipitation (IP) experiments at dilutions ranging from 1:50 to 1:200, allowing for isolation and enrichment of p53 protein from complex biological samples prior to analysis . When using this antibody for any application, it is advisable to include appropriate positive and negative controls to ensure specificity and validate experimental results .

How should TP53 (Ab-15) Antibody be stored and handled to maintain its activity?

For long-term preservation, TP53 (Ab-15) Antibody should be stored at -20°C in aliquots to minimize repeated freeze-thaw cycles that can degrade antibody quality and performance . The antibody is typically supplied in a storage buffer containing PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain stability during storage . For short-term use and frequent access, the antibody can be stored at 4°C for up to one month without significant loss of activity . When handling the antibody, it is important to note that it contains sodium azide, which is a hazardous substance that should be handled with appropriate precautions by trained personnel . Before use, allow the antibody to equilibrate to room temperature and gently mix by inverting the vial rather than vortexing, which can cause protein denaturation. Proper storage and handling practices are crucial for maintaining antibody specificity and sensitivity across experimental replicates over time . When preparing working dilutions, use fresh, sterile buffers and store any diluted antibody at 4°C for short periods only.

What are the cross-reactivity properties of TP53 (Ab-15) Antibody?

TP53 (Ab-15) Antibody demonstrates reactivity across multiple species including human, mouse, rat, and monkey, making it valuable for comparative studies across different model systems . The cross-reactivity is attributed to the high conservation of the epitope sequence (amino acids 13-17, P-L-S-Q-E) in the p53 protein across these species . Researchers should note that while the antibody detects total p53 protein regardless of its phosphorylation state, it does not cross-react with other members of the p53 family such as p63 or p73, due to sequence divergence in the epitope region . This specificity allows for confident detection of p53 without interference from related proteins in experimental systems. When working with less common species not listed in the product specifications, preliminary validation experiments are recommended to confirm reactivity before proceeding with full-scale studies . The consistent cross-reactivity profile across multiple species makes this antibody particularly useful for translational research where findings from animal models are compared with human samples.

How can TP53 (Ab-15) Antibody be used in conjunction with phospho-specific p53 antibodies in experimental designs?

What methodological considerations are important when using TP53 (Ab-15) Antibody for quantifying p53 levels in stress response studies?

When designing stress response studies using TP53 (Ab-15) Antibody, researchers should implement rigorous time-course experiments that capture both early and late phases of the p53 response, as p53 dynamics often follow oscillatory patterns after stress induction . Sample preparation is critical; cell lysis buffers should contain protease inhibitors to prevent p53 degradation during extraction, and phosphatase inhibitors are essential if subsequent analysis with phospho-specific antibodies is planned . For Western blot quantification, researchers should carefully optimize loading controls, as common housekeeping proteins like GAPDH can be affected by cellular stress conditions; consider using total protein normalization methods such as stain-free technology or REVERT total protein stains for more accurate quantification . When comparing p53 levels across different stress conditions (e.g., UV radiation, ionizing radiation, chemical agents), standardize the stress dose to achieve comparable biological effects rather than using identical physical or chemical doses . The following table outlines methodological considerations for different experimental techniques when quantifying p53 responses to stress:

How can contradictory results between TP53 (Ab-15) Antibody and other p53 antibodies be interpreted and resolved?

When faced with discrepancies in results between TP53 (Ab-15) Antibody and other p53 antibodies, researchers should first consider the epitope locations of each antibody and how these might be affected by protein conformation, post-translational modifications, or protein-protein interactions in the experimental context . The N-terminal epitope recognized by TP53 (Ab-15) (amino acids 13-17) could potentially be masked in certain protein complexes, while other antibodies targeting different regions might still detect p53 in these complexes . A systematic approach to resolving contradictions involves running parallel validations using multiple detection methods such as Western blotting, immunoprecipitation followed by mass spectrometry, and immunofluorescence to triangulate the true p53 status . Researchers should also consider utilizing genetic approaches, such as siRNA knockdown or CRISPR-Cas9 gene editing of p53, to generate definitive negative controls that can help ascertain antibody specificity . In cases where differences persist, it is valuable to examine the experimental conditions that might affect epitope accessibility, such as denaturation methods in Western blotting, fixation protocols in immunohistochemistry, or buffer compositions that might influence protein conformation . The table below provides a troubleshooting framework for resolving contradictory results between different p53 antibodies:

What are the optimal conditions for using TP53 (Ab-15) Antibody in Western blot applications?

For optimal Western blot performance with TP53 (Ab-15) Antibody, sample preparation should begin with efficient cell lysis using RIPA buffer containing freshly added protease inhibitors to prevent p53 degradation during extraction . Protein loading should be carefully optimized; for detecting endogenous p53 in unstressed cells, higher protein amounts (30-50 μg per lane) may be necessary due to typically low basal p53 levels, while stressed or transformed cells with elevated p53 may require less sample (10-20 μg) to prevent signal saturation . Transfer conditions should be optimized for proteins in the 50-55 kDa range, typically using wet transfer at 100V for 60-90 minutes or semi-dry transfer at 25V for 30 minutes with methanol-containing transfer buffer to efficiently move p53 to the membrane . For blocking, 5% non-fat dry milk in TBST is generally effective, though some researchers prefer 5% BSA when subsequent detection with phospho-specific antibodies is planned . The recommended dilution range for TP53 (Ab-15) in Western blot applications is 1:500 to 1:1000, but this should be empirically determined for each experimental system to achieve optimal signal-to-noise ratio . When developing the blot, enhanced chemiluminescence (ECL) detection systems provide good sensitivity for p53 detection, with exposure times adjusted based on p53 expression levels in the experimental samples.

What controls and validation steps should be incorporated when using TP53 (Ab-15) Antibody in new experimental systems?

When implementing TP53 (Ab-15) Antibody in a new experimental system, researchers should include a comprehensive set of controls beginning with positive controls such as cell lines known to express p53 (e.g., MCF-7 for wild-type p53 or HT-29 for mutant p53) and negative controls such as p53-null cell lines (e.g., H1299) to confirm antibody specificity . Validation should include peptide competition assays, where pre-incubation of the antibody with the immunizing peptide should abolish specific staining, providing evidence for epitope-specific binding . For genetic validation, researchers can employ siRNA or shRNA knockdown of p53, or use CRISPR-Cas9 engineered p53-knockout cell lines alongside parental cells to demonstrate signal specificity . When applying the antibody to tissue samples, include appropriate isotype controls matched to the antibody's host species and compare staining patterns with previously validated antibodies targeting different p53 epitopes . The table below outlines essential controls for validating TP53 (Ab-15) Antibody in various applications:

How can TP53 (Ab-15) Antibody be optimized for immunohistochemistry and immunofluorescence applications?

For successful immunohistochemistry (IHC) with TP53 (Ab-15) Antibody, antigen retrieval is a critical step that should be optimized; heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for 15-20 minutes typically provides good results for p53 detection in formalin-fixed, paraffin-embedded (FFPE) tissues . The antibody dilution for IHC applications generally ranges from 1:50 to 1:200, but should be determined empirically for each tissue type and fixation method to achieve optimal signal-to-background ratio . For immunofluorescence (IF) applications, fixation protocols significantly impact epitope accessibility; 4% paraformaldehyde for 15-20 minutes at room temperature often preserves p53 antigenicity while maintaining cellular morphology, but methanol fixation may be preferable for certain applications requiring better nuclear antigen exposure . Permeabilization conditions should be carefully optimized; 0.1-0.3% Triton X-100 for 5-10 minutes is commonly effective for nuclear proteins like p53, but excessive permeabilization can disrupt cellular architecture and increase background . The table below provides optimization guidelines for different sample types:

What methodological approaches can enhance detection sensitivity when working with low p53 expression levels?

When working with samples containing low p53 expression levels, implementing signal amplification techniques can significantly enhance detection sensitivity with TP53 (Ab-15) Antibody . For Western blot applications, consider using high-sensitivity chemiluminescent substrates with extended exposure times, or switching to fluorescent secondary antibodies and detection systems that offer better quantitative linearity across a wider dynamic range . Sample enrichment through immunoprecipitation prior to Western blotting can concentrate p53 from larger sample volumes, improving detection of low-abundance p53 forms; use 1-2 mg of total protein lysate with 2-5 μg of TP53 (Ab-15) Antibody for effective pulldown . In immunohistochemistry and immunofluorescence applications, tyramide signal amplification (TSA) can enhance sensitivity by 10-100 fold compared to conventional detection methods, allowing visualization of low-abundance p53 in tissue sections or cells . For flow cytometry, consider using brighter fluorophores such as PE or APC rather than FITC, and implementing multi-layer detection systems (primary antibody → biotinylated secondary antibody → streptavidin-fluorophore) to amplify signal . The table below compares different signal enhancement approaches:

How can non-specific signals and background issues be addressed when using TP53 (Ab-15) Antibody?

When encountering non-specific signals or high background with TP53 (Ab-15) Antibody, several optimization strategies can be implemented based on the specific application . For Western blot applications, increasing the stringency of washing steps by using TBST with higher Tween-20 concentrations (0.1% to 0.3%) and extending wash durations to 10-15 minutes per wash can effectively reduce background; additionally, optimizing the blocking solution (comparing BSA versus milk, or increasing blocking agent concentration to 5-10%) can address non-specific binding issues . In immunohistochemistry, background issues often stem from endogenous peroxidase activity or biotin; implementing hydrogen peroxide treatment (3% H₂O₂ for 10 minutes) prior to antibody incubation and using avidin-biotin blocking kits for biotin-based detection systems can significantly reduce background . For immunofluorescence applications, autofluorescence can be minimized by treating samples with 0.1-1% sodium borohydride for 5-10 minutes before antibody incubation, or by using Sudan Black B (0.1-0.3% in 70% ethanol) post-staining to quench lipofuscin-related autofluorescence . Across all applications, diluting the antibody in the same buffer used for blocking rather than in PBS alone can reduce non-specific interactions, and including 0.1-0.5% non-ionic detergents such as Triton X-100 or NP-40 in antibody diluents can further enhance specificity .

What strategies can resolve ambiguous results when analyzing p53 in complex biological samples?

When faced with ambiguous results during p53 analysis in complex biological samples, implementing orthogonal detection approaches can provide clarity and confidence in data interpretation . Researchers should consider using multiple antibodies targeting different p53 epitopes to distinguish between specific and non-specific signals; combining TP53 (Ab-15) with antibodies recognizing the central domain (PAb240 or DO-1) and C-terminal region can create a more comprehensive detection profile . In challenging samples like tumor tissues with heterogeneous p53 expression or modifications, combining immunohistochemistry with laser capture microdissection followed by Western blotting or PCR-based analyses can correlate protein detection with genetic status . For distinguishing between wild-type and mutant p53 forms that may co-exist in samples, researchers can couple immunodetection with functional assays such as reporter assays measuring p53 transcriptional activity or chromatin immunoprecipitation to assess p53 binding to target gene promoters . The table below outlines a strategic approach to resolve ambiguous p53 detection results:

How should researchers interpret changes in p53 detection patterns following experimental treatments or genetic manipulations?

What considerations are important when comparing p53 data across different cell lines or tissue types using TP53 (Ab-15) Antibody?

When comparing p53 data across different biological systems using TP53 (Ab-15) Antibody, researchers must account for several variables that can significantly impact interpretation . First, consider the genetic background of each system, particularly the TP53 mutation status, as mutations can dramatically alter p53 stability, localization, and antibody epitope accessibility; sequencing the TP53 gene in each cell line or obtaining this information from databases like COSMIC or IARC TP53 Database is advisable before making comparisons . Second, evaluate baseline p53 regulatory network components across systems, as variations in MDM2, MDMX, or ARF expression can significantly influence basal p53 levels and stress responses even with identical TP53 genotypes . Third, account for tissue-specific factors that modify p53 function, such as differentiation state, proliferation rate, and microenvironmental conditions, all of which can affect p53 behavior independently of genetic differences . The table below outlines important considerations for cross-system comparisons:

How can TP53 (Ab-15) Antibody be integrated into single-cell analysis techniques for studying p53 heterogeneity?

Integrating TP53 (Ab-15) Antibody into single-cell techniques offers powerful approaches for dissecting p53 heterogeneity within seemingly homogeneous populations, revealing insights into cellular decision-making and treatment responses . For single-cell immunofluorescence applications, researchers can combine TP53 (Ab-15) with cell cycle markers (e.g., EdU incorporation, PCNA) and downstream effector proteins (e.g., p21, cleaved caspase-3) to correlate p53 expression with functional outcomes at the individual cell level . In flow cytometry and mass cytometry (CyTOF) applications, TP53 (Ab-15) can be incorporated into multi-parameter panels after careful optimization of fixation, permeabilization, and staining conditions; for flow cytometry, conjugating the antibody to bright fluorophores like PE or APC is recommended, while for CyTOF, metal-conjugated antibodies provide superior multiplexing capabilities . When implementing these approaches, researchers should establish antibody specificity at the single-cell level using appropriate controls (including p53-null cells) and optimize signal-to-noise ratio through titration experiments . The table below outlines integration strategies for different single-cell techniques:

What are the considerations for using TP53 (Ab-15) Antibody in studying p53 dynamics in live cell imaging approaches?

While TP53 (Ab-15) Antibody is not directly applicable to live cell imaging due to its inability to penetrate intact cell membranes, researchers can implement complementary approaches that allow correlation between fixed-cell antibody detection and live-cell p53 dynamics . One strategy involves establishing parallel cultures where some samples are processed for live imaging using fluorescently-tagged p53 constructs (e.g., p53-GFP), while matching samples are fixed at defined time points for TP53 (Ab-15) Antibody staining; this allows validation that the tagged p53 behaves similarly to endogenous p53 as detected by the antibody . Another approach utilizes cell-permeable small molecule fluorescent probes that bind specifically to p53 for live imaging, followed by fixation and TP53 (Ab-15) Antibody staining to confirm specificity of the live signal . For studying rapid p53 dynamics, researchers can implement optogenetic p53 systems where p53 activity can be modulated by light, with subsequent fixation and antibody detection to confirm the effects on endogenous p53 status and downstream pathways . The table below compares approaches for correlating live imaging with antibody-based detection:

How can TP53 (Ab-15) Antibody contribute to understanding p53 function in three-dimensional culture systems and organoids?

TP53 (Ab-15) Antibody can be effectively adapted for studying p53 biology in three-dimensional (3D) culture systems and organoids, providing insights into p53 function in more physiologically relevant contexts compared to traditional 2D cultures . For whole-mount immunofluorescence of 3D cultures, researchers need to implement optimized protocols with extended permeabilization (0.5% Triton X-100 for 30-60 minutes) and antibody incubation times (overnight at 4°C) to ensure complete penetration into the structures; antibody concentration may need to be increased to 1:50-1:100 compared to 2D applications . Alternatively, researchers can cryosection or paraffin-embed 3D cultures and organoids before proceeding with standard immunohistochemistry protocols, which allows for better antibody access but sacrifices the intact 3D architecture . For dynamic studies in organoids, researchers can establish p53 reporter systems (e.g., p53-responsive GFP expression) for live monitoring, followed by fixation and TP53 (Ab-15) Antibody staining at endpoints to correlate reporter activity with endogenous p53 status across different regions of the organoid . The table below provides methodological guidelines for different 3D culture applications:

What considerations are important when using TP53 (Ab-15) Antibody in conjunction with high-throughput screening approaches?

When integrating TP53 (Ab-15) Antibody into high-throughput screening workflows, researchers must adapt protocols to ensure reliability and reproducibility across large sample sets while maintaining sensitivity and specificity . For plate-based immunoassays, antibody performance should be validated across the dynamic range expected in the screen, with careful optimization of fixation, blocking, and antibody concentration to minimize well-to-well variability; typically, slightly higher antibody concentrations (1:100-1:500) than used in traditional Western blots may be necessary to ensure consistent detection across all samples . Automation-compatible protocols should be developed with simplified washing steps and robust detection systems, such as HRP-conjugated secondary antibodies with chemiluminescent substrates for plate reader detection or fluorescent secondary antibodies for high-content imaging . To ensure quality control across plates and batches, each plate should include internal standards (positive and negative controls) positioned strategically to detect and correct for positional effects and edge artifacts . The table below outlines considerations for different high-throughput applications:

Future directions in p53 antibody development and applications

The field of p53 research continues to evolve with emerging technologies enabling increasingly sophisticated analyses of p53 biology, with antibodies like TP53 (Ab-15) serving as foundational tools that will be complemented by next-generation approaches . Single-molecule detection methods, such as proximity ligation assays and super-resolution microscopy, are beginning to reveal previously undetectable p53 interactions and subcellular localizations, requiring even greater antibody specificity and sensitivity . The integration of spatial transcriptomics with highly multiplexed antibody-based imaging technologies (e.g., CODEX, 4i) promises to revolutionize our understanding of p53's tissue-specific functions by simultaneously visualizing p53 protein expression alongside its transcriptional outputs and interaction partners at single-cell resolution within intact tissues . Development of antibodies recognizing specific p53 conformational states beyond simple wild-type/mutant distinctions could provide deeper insights into the functional heterogeneity of p53 in different cellular contexts and disease states . As the repertoire of p53 isoforms and their roles in normal physiology and disease continues to expand, the development of isoform-specific antibodies will be crucial for dissecting their unique contributions . Looking forward, the combination of traditional antibody-based approaches with CRISPR-based genomic tagging strategies may provide the best of both worlds: enabling live visualization of endogenous p53 dynamics while allowing correlation with fixed-cell antibody-based detection of specific modifications and interactions.